Germline mutations in the von Hippel-Lindau (VHL) tumor suppressor gene predispose individuals to clear cell renal carcinomas, hemangioblastomas, and pheochromocytomas. The VHL gene product forms an ubiquitin E3 ligase complex, with regulation of hypoxia-inducible factor alpha (HIF-α) as its best known function. Lack of VHL expression has been shown previously to sensitize renal cells to apoptosis caused by certain cellular stresses. In this report, the role of HIF-α in apoptosis was investigated using two parent VHL-null renal carcinoma cell lines. 786-O and RCC10 renal carcinoma cell lines with manipulated levels of VHL, HIF-1α, or HIF-2α were subjected to cellular stresses and analyzed by western blotting for the abundance of apoptotic markers. Cell lines expressing mutant VHL proteins that were unable to regulate HIF-α had increased levels of apoptosis when irradiated with ultraviolet (UV) light. The influences of the two major isoforms of HIF-α, HIF-1α and HIF-2α, on apoptosis, were
Small Renal tumors: Are patients being properly counseled? With your host, Dr. Gary Kohn, is Robert Houston Thompson, Urologic Oncology Fellow, at Memorial Sloan Kettering Cancer Center in New York. Join the discussion as Dr. Thompson covers the management of small renal tumors, highlighting survival rates of patients treated with partial vs. radical nephrectomies.
TY - JOUR. T1 - Radiofrequency ablation of small renal cortical tumours in healthy adults. T2 - Renal function preservation and intermediate oncological outcome. AU - Stern, Joshua M.. AU - Gupta, Amit. AU - Raman, Jay D.. AU - Cost, Nicholas. AU - Lucas, Steven. AU - Lotan, Yair. AU - Raj, Ganesh. AU - Cadeddu, Jeffrey A. PY - 2009/9/1. Y1 - 2009/9/1. N2 - OBJECTIVES To present the glomerular filtration rate (GFR) and oncological outcomes in a series of patients with cT1a renal cortical tumours treated with radiofrequency ablation (RFA), a non-ischaemic minimally invasive ablative method, as nephron-sparing surgery gives excellent oncological outcomes and preserves renal function. PATIENTS AND METHODS Healthy (American Society of Anesthesiologists, ASA, I and II) patients with cT1a renal masses were identified, and clinical and radiographic data were reviewed to assess indications, complications, radiological evidence of disease recurrence, and renal function. Changes in GFR were calculated. ...
Cases reported • Kidney Neoplasms; Cancer of Kidney; Kidney Cancer; Renal Cancer. On-line free medical diagnosis assistant. Ranked list of possible diseases from either several symptoms or a full patient history. A similarity measure between symptoms and diseases is provided.
TY - JOUR. T1 - In-phase signal intensity loss in solid renal masses on dual-echo gradient-echo MRI. T2 - Association with malignancy and pathologic classification. AU - Childs, David D.. AU - Clingan, M. Jennings. AU - Zagoria, Ronald J.. AU - Sirintrapun, Joseph. AU - Tangtiang, Kaan. AU - Anderson, Andrea. AU - Leyendecker, John R.. PY - 2014/10/1. Y1 - 2014/10/1. N2 - OBJECTIVE. The purposes of this study were to determine the prevalence of in-phase signal intensity loss on dual-echo gradient-echo MRI in solid renal masses using visual and quantitative techniques and to test for any association between in-phase signal intensity loss and pathologic classification. MATERIALS AND METHODS. The renal MRI studies of 177 patients (192 solid masses consisting of 166 renal cell carcinomas [RCCs], four malignant non-RCCs, and 22 benign tumors) were qualitatively reviewed by two blinded readers for visual evidence of relative in-phase signal intensity loss. For lesions without visual evidence, ...
Malignant Kidney Neoplasm except Renal Pelvis (Malignant Neoplasm of Kidney except Renal Pelvis): Read more about Symptoms, Diagnosis, Treatment, Complications, Causes and Prognosis.
Metastasis-associated protein 2 (MTA2) was previously known as a requirement to maintain malignant potentials in several human cancers. However, the role of MTA2 in the progression of renal cell carcinoma (RCC) has not yet been delineated. In this study, MTA2 expression was significantly increased in RCC tissues and cell lines. Increased MTA2 expression was significantly associated with tumour grade (p = 0.002) and was an independent prognostic factor for overall survival with a high RCC tumour grade. MTA2 knockdown inhibited the migration, invasion, and in vivo metastasis of RCC cells without effects on cell proliferation. Regarding molecular mechanisms, MTA2 knockdown reduced the activity, protein level, and mRNA expression of matrix metalloproteinase-9 (MMP-9) in RCC cells. Further analyses demonstrated that patients with lower miR-133b expression had poorer survival rates than those with higher expression from The Cancer Genome Atlas database. Moreover, miR-133b modulated the 3′untranslated
Activation of the proto-oncogene ras may play a critical role in the development and rapid progression of different types of human cancers, including renal cancer. It has been shown that the Ras pathway can mediate pro-survival signals in cancer cells by inhibiting cellular apoptosis. It is established that the cytoprotective enzyme heme oxygenase-1 (HO-1) is over-expressed in several cancers, and may play a significant role in the growth and metastasis of tumors by inducing cell survival pathways. However, it is not known if there is an association between Ras activation and HO-1 over-expression in cancer. We have recently demonstrated that the treatment of human renal cancer cells with the immunosuppressive agent cyclosporine may activate the H-Ras pathway, and promote a rapid progression of the disease. We have also shown that HO-1 is over-expressed in human renal cancer, and plays a key role in the survival of renal cancer cells by inhibiting cellular apoptosis. Here, we wished to analyze if ...
Background 209 000 new cases of renal carcinoma are diagnosed each full year worldwide and new therapeutic focuses on are urgently needed. service and improved NMU appearance. On the other hand, reductions of HIF in VHL faulty RCC cells via siRNA of HIF- subunits or appearance of Type 2C mutant VHLh decreased NMU appearance amounts. We also display that renal tumor cells specific a practical NMU receptor (NMUR1), and that NMU stimulates migration of renal tumor cells. Results These results recommend that NMU may work in an autocrine style, advertising development of kidney tumor. Hypoxia and HIF appearance are regularly noticed in many non-renal malignancies and are connected with a poor diagnosis. Our research increases the probability that HIF might drive NMU phrase in non-renal tumours also. Results Kidney tumor is responsible for 102 000 fatalities per yr diagnosis and worldwide is generally poor [1]. Crystal clear cell renal cell carcinoma (CCRCC) can be the commonest type of kidney tumor ...
Everolimus (RAD001, Afinitor) is an mTOR inhibitor FDA-approved for the treatment of patients with advanced clear cell renal cancer (RCC) after failure of treatment with sunitinib or sorafenib, or both drugs. It targets the mammalian target of rapamycin (mTOR) complex inhibiting a serine/threonine kinase regulating PI3K/AKT signaling pathway. Previous evidences demonstrated that the activation of the chemokine receptor CXCR4 involved the mTOR pathway and that CXCR4 was overexpressed in RCC. Recently, also the deorphanized chemokine receptor CXCR7 was described in RCC and defined as an independent prognostic factor. Nevertheless, little is known about the CXCR4-CXCL12-CXCR7-induced signalling. Aim of the study was to investigate if the CXCL12/CXCR4/CXCR7 complex could transduce the signal through mTOR identifying new therapeutic targets. In human renal cancer cells (RXF393, A498) treatment with CXCL12, the CXCR4 and CXCR7 ligand, induced mTOR pathway, as demonstrated through p70S6K and eukaryotic ...
Sunitinib plays an important role in managing the metastatic renal cell cancer (mRCC). Sunitinib-induced hypothyroidism is a common side-effect of the drug.
We found that knocking down these transcripts in vitro with antisense oligonucleotide (ASO) induces selective death of several human and murine tumor cell lines without affecting viability of normal cells. The aim of this study was to evaluate in vitro and in vivo, the therapeutic value of silencing the ASncmtRNA with ASO in human cell lines/primary cultures and in A498 xenograft and Patient derived xenograft (PDX) RCC model.. Methods: For the in vitro studies we used different human renal carcinoma cell lines (786-O, Caki-1, A498) and 6 primary cultures derived from RCC patients. Knock down of the ASncmtRNA was achieved by transfection of ASO targeted to the loop region of these transcripts (Andes-1537). As control, we used ASO with unrelated sequence (NR-ASO). Cell death was evaluated with FACS by PI and tripan exclusion assay and the decrease in tumorigenicity was determined by sphere assay. The apoptosis hallmarks evaluated were Caspase activation, DNA fragmentation and phosphatidylserine ...
Histologically documented metastatic renal cell cancer with a component of clear cell histology.. - Evidence of measurable disease.. - Patients with mRCC must have received no prior systemic first-line therapy or must have progressive disease per RECIST (version 1.0) after one prior systemic first line regimen for metastatic disease containing sunitinib, cytokine(s), or both.. ...
The International Consortium for the Investigation of Renal Malignancies (I-ConFIRM) was formed to promote international, multidisciplinary collaborations to advance our understanding of the etiology and outcomes of kidney cancer.
Kidney Cancer, also known as renal cancer is a type of cancer which forms tumours in different parts of Kidneys.. Almost all kidney cancers initially appear in the lining of tiny tubes of the Kidney and such kidney cancer is called renal cell carcinoma. The good thing about this cancer is that it can be detected earlier than any other type of cancer, and hence its spreading can be stopped. But even in the case of kidney cancer, tumours may grow large before it is detected.. The main job of Kidneys is to purify the blood by filtering harmful substances and to make urine. Thus any urine related problem can be early signs of kidney cancer. Just like any other form of cancer, even kidney cancers have some stages.. Stages of Kidney Cancer. There are various stages of Kidney Cancer. As the steps grow, Kidney Cancer becomes more dangerous. The stages are -. Stage I. A tumour is smaller than 7, which are only in the Kidney.. Stage II. A tumour is equal to or larger than 7, which are only in the ...
New life-saving treatments for Colorectal cancer in clinical trial on A Phase IIb, Nonrandomized, Open-Label Trial with Mouse Renal Adenocarcinoma (RENCA) Cell Containing Agarose-Agarose Macrobeads Compared with Best Supportive Care in Patients with Treatment-Resistant, Metastatic Colorectal Carcinoma
Learn how Avastin® (bevacizumab) is designed to work for the treatment of metastatic kidney cancer (mRCC) Metastatic Colorectal Cancer (mCRC) Avastin is approved to treat metastatic colorectal cancer (mCRC) for: First- or second-line treatment in combination with intravenous 5-fluorouracil-based chemotherapy Second-line treatment when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy after cancer progresses following a first-line treatment that includes Avastin. Avastin is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body. Glioblastoma (GBM) Avastin is approved to treat glioblastoma (GBM) when taken alone in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM). The effectiveness of Avastin in rGBM is based on tumor response. Currently, no data have shown whether or not Avastin improves disease-related symptoms or survival in people with rGBM. Non-Small Cell Lung Cancer
WEDNESDAY, Nov. 30, 2016 (HealthDay News) -- An experimental drug may show promise in treating kidney cancer, researchers say.. The drug CB-839 is the first to target an enzyme that cancer cells require to stay alive, researchers said. This stage 1 clinical trial found that the drug was effective in most patients with advanced kidney cancer when used in combination with another cancer drug called everolimus (Afinitor, Zortress).. In the 15 patients in the study, the dual treatment controlled tumors in 93 percent of the patients, who had either clear cell or papillary renal cell cancer. Tumors shrank by more than 30 percent in one patient, were stable in 13 patients, and grew by more than 20 percent in one patient.. Clear cell is the most common form of kidney cancer, accounting for 75 percent of cases, the researchers said. All 12 patients with this type of kidney cancer had their disease controlled. Papillary renal cell cancer is the next most common form of kidney cancer and accounts for 10 ...
Metastatic renal cell carcinoma is one of the most treatment-resistant malignancies and patients have dismal prognosis, said Dr. George M. Yousef, a laboratory pathologist. Identification of markers that can predict the potential of metastases will have a great impact on improvement patient outcomes.. Dr. Yousefs research appears online in the journal Molecular & Cellular Proteomics.. Kidney cancer in general is very aggressive and has a high chance of metastasis, or spreading to other organs. The five-year survival rate for metastasized kidney cancer is less than 10 per cent. Although imaging technology has led to increased detection of kidney tumours, 25 to 30 per cent have already spread by the time they are found.. Using a mass spectrometer, Dr. Yousef identified 29 proteins that change when cancer cells spread from the original site of the kidney tumour. All 29 proteins have been previously been linked to other malignancies.. Dr. Yousef said if physicians can determine which kidney ...
Mucinous tubular and spindle cell carcinoma (MTSCC) is rare in renal cell carcinoma (RCC) and usually demonstrates a low nuclear grade and a better prognosis compared with other RCCs. The authors present a case report of MTSCC containing an area of Fuhrman nuclear grade 3, in addition to an area with a micropapillary pattern. An 82-year-old man consulted a hospital due to macrohematuria, and a tumor in the right kidney was detected. The tumor was resected and histologically examined. The tumor consisted of various growth patterns: Elongated tubular structure, a papillary structure containing a micropapillary pattern and solid pattern with spindle cells ...
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...
RCC has a unique biological profile, with a long dormancy of metastasis (3) . Some patients with RCCs believed to be curable with radical nephrectomy develop distant metastasis 5-10 years after surgery. RCC probably spreads mainly by a hematogenous mechanism. It was reported that serum microsatellite alterations were found in more than 50% of patients with RCC (16 , 17) ; this probably reflects the hematogenous mechanism by which renal tumors spread. Thus, it would be very useful to identify a tumor marker for RCC for monitoring patients after surgery and determining postoperative adjuvant chemotherapy.. It was recently reported that MN/CA9 might be useful as a diagnostic marker for RCCs (18 , 19) . The VHL tumor suppressor gene was isolated in 1993 (20) . Somatic mutations of the VHL gene have been detected in up to 60% of sporadic clear cell RCCs, the predominant form of kidney cancer (11, 12, 13) . In this study, we demonstrated that nested RT-PCR using VHL gene mutation can detect the ...
Kidneys are not exempted from having cancer. Today, a lot of people suffer from kidney Cancer and are taking various medications as treatment. Kidney tumor is a rare form of Cancer and the cure of Kidney Cancer depends on the stage at which the kidney Cancer was detected in a patient. Being knowledgeable of this disease helps you prepare your body for the treatment, and in some cases, avoid having this problem in the long run.. Several vital information you must learn about kidney cancer includes the following:. Kidney Cancer Statistics. Understanding kidney cancer, also known as renal cancer, through numbers is important for people today. According to American Cancer Societys 2013 forecast, approximately 65,000 new cases of cancer will be listed this year, with two-thirds of them being male patients. Estimated death statistics due to this problem is around 13,500 cases.. Patients who have been diagnosed with renal cancer are concerned about the 5-year survival rates noted down on this disease. ...
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
Image-guided ablation of primary renal cancers may be performed with minimal morbidity and produce excellent results in terms of long-term survival.
Kidney Cancer: What is Kidney Cancer?, Kidney Cancer occurs when healthy cells in one or both kidneys grow out of control and form a lump (called a tumor). Renal cell carcinoma is the most common type of kidney cancer in adults.
Congress : ESMO. Authors : S Negrier, N Rioux-Leclercq, A Ravaud, G Gravis, L Geoffrois, C M Chevreau, F Rolland, E Blanc, C Segura-Ferlay, D Perol, M Gross Goupil, S Dermeche, A Flechon, L Albiges, B Escudier.. Experts group or program : Groupe détude des tumeurs urogénitales (GETUG). PRC represents 10-15% of renal carcinomas; there is no standard treatment at the metastatic stage. Few trials were conducted with sunitinib, everolimus and more recently savolitinib, with disappointing response rates. Axitinib, an inhibitor of VEGF receptors, indicated as 2d line treatment in advanced renal cell carcinoma was investigated.. En savoir plus. ...
ASCO GU 2020, combination immunotherapy and immunotherapy/anti-angiogenic therapy combinations, phase I-II study of sitravatinib combined with nivolumab in patients who have previously progressed on TKI therapy for accRCC
Title:Current Management of Fetal and Neonatal Renal Tumors. VOLUME: 11 ISSUE: 3. Author(s):Michael Berger and Dietrich von Schweinitz. Affiliation:Department of Pediatric Surgery, Dr. von Hauner Childrens Hospital, Ludwig Maximilians University Munich, Lindwurmstrasse 4, 80337 Munich, Germany.. Keywords:Fetal renal tumors, fetal tumors, neonatal tumors.. Abstract:Fetal and neonatal renal tumors are rare. Nevertheless, in-depth understanding of their features can lead to early recognition and appropriate treatment, ultimately benefiting outcome. Despite the many obvious similarities, important distinctions exist between these tumors and their counterparts in older children. Likewise, some important distinctions exist between fetal tumors on the one hand and neonatal tumors on the other. In this article, we review the pertinent features of fetal and neonatal renal tumors and specifically point out the important individualities in their clinical management.. ...
About 6% to 7% of kidney cancers begin not in the kidney itself, but in the renal pelvis, the point where the kidney joins the ureter (the tube running from the kidney to the bladder). These tumors are called transitional cell carcinomas, and are made up of cancer cells different from those that characterize RCC. Research indicates these tumors are caused by cigarette smoking. A relatively rare form of kidney cancer, Wilms tumor (also known as nephroblastoma) accounts for about 5% to 8% of kidney tumors in children. Renal sarcoma is a rare disease of the kidneys connective tissues that accounts for less than 1% of all kidney tumors.
What is kidney cancer? Kidney Cancer Canada provides kidney cancer facts and kidney cancer information about kidney cancer through kidney cancer support group.
Renal Metastasis of Esophageal Squamous Cell Carcinoma- A Case Report and Literature Review. PubMed, SCI, Scopus, ESCI, PMC indexed
Gyula Kovacs, Mohammed Akhtar, Bruce J. Beckwith, Peter Bugert, Colin S. Cooper, Brett Delahunt, John N. Eble, Stewart Fleming, Börje Ljungberg, L. Jeffrey Medeiros, Holger Moch, Victor E. Reuter, Eberhard Ritz, Goran Roos, Dietmar Schmidt, John R. Srigley, Stephan Störkel, Eva van den Berg, Bert Zbar ...
I need all my fans to pray for me. Doctor just told me I have cancer on my kidneys. Prayer is power, thats why Im letting the world know prayfaboosie.. Kidney cancer is rare. Only 65,000 cases of kidney cancer are reported annually in the United States. Compare that with 1.8 million lung cancer diagnoses reported in 2012. Kidney cancer accounts for only 2% of all cancer cases reported in the U.S.. CAUSES. The factors that are at high risk for kidney cancer include family history of kidney cancer, smoking, taking over the counter NSAIDs pain medicine (Aspirin, Motrin, Aleve, Naprosyn); hepatitis C, and dialysis.. SIGNS and SYMPTOMS. Signs and symptoms include abdominal distention, abdominal mass (hard or soft), abdominal pain, blood in urine.. TREATMENT Treatment for kidney cancer depends on the stage of cancer (1-4). Treatment includes chemotherapy and radiation, cancer drugs and immunotherapy, partial or total nephrectomy (removal of affected kidney).. 5-year survival rate is 73% in the ...
I am new to this forum. I have been reading quite a number of discussions on this forum and found them very informative and helpful. I am a not so old guy (61 years old) with pretty good health generally. However, last Dec, I was found to have a small renal tumor in my left kidney (about 1.6 cm) which was highly likely to be RCC. After some further imaging, I went through an open partial nephrectomy at end Jan this year. The surgery was successful. The path report shows that the tumor was stage T1a RCC clear cell grade 3. No spread. All negative margins. What I am concerned is about the grade 3. I wonder why such a small tumor could be grade 3. I will have a post-op follow-up visit with the urological surgeon and wonder what I need to discuss with him. Also I will be travelling by air back to my southeast hometown from NYC (about 2-hr flight) in a week (about 3.5 weeks after the surgery), I wonder if that should be OK. My incision looks healed, but there is still some pain inside. Thanks for ...
This was a non-interventional, multicenter study to evaluate efficacy and safety of intravenous Avastin in combination with interferon alpha-2a for first-line
Renal Cell Cancer or Hypernephroma is a serious pathological condition of the kidney. Read the Causes, Symptoms, Treatment, Diagnosis, Prognosis, Complications.
The kidneys are paired bean-like organs located in the back of the abdominal cavity in the retroperitoneum. The kidneys play a large role in the regulation of wastes, electrolytes, water, blood pressure and acid-base balance throughout the body. Although it is normal to have two kidneys, it is quite possible to live with just one.. The most common type of kidney cancer is called renal cell carcinoma (RCC). Risk factors include smoking, regular use of non-steroidal anti-inflammatories such as ibuprofen and naproxen, a family history of kidney cancer, and renal disease requiring dialysis. Most commonly, kidney cancer is detected incidentally on imaging for some other purpose and has no signs or symptoms. In cases where the cancer has formed a larger tumor, a patient may experience flank pain, a mass in the abdomen, or blood in the urine that is either visable or apparent on a dipstick test. Other tests to help stage the extent of kidney cancer may include a CT scan of the abdomen and pelvis to ...
1) After treatment for kidney cancer, routine life-long surveillance is necessary with periodic assessment by a physician, blood tests and X-rays. Unfortunately there are no proven ways to prevent recurrence 2) Patients with only one kidney after removal of the other usually have no adverse effects or handicaps although contact sports and drugs that can damage the kidney should be avoided. 3) There are many factors that affect outcome after treatment for kidney cancer. The two most important prognostic factors are tumor stage and grade. Higher stage and grade implies a lower chance of cure. 4) For kidney tumors, needle biopsy is usually not indicated because more than 90 percent of solid kidney tumors are cancer and biopsies have a significant rate of false-negatives. 5) In patients without lymphadenopathy, lymph node dissection does not improve the survival. In patients with enlarged regional lymph nodes and distant metastasis, recent data suggest that lymph node dissection improves survival. ...
I investigated the influence of the phosphatidylinositol 3-kinase (PI3K)Akt pathway on HSF1 activation status. Despite effecting significant up-regulation of the PI3k/Akt pathway with insulin and insulin-like growth factor-1 (IGF-1), I did not demonstrate any change in the HSF1 trimerisation state, DNA-binding ability or nuclear localisation in renal adenocarcinoma cells (ACHN). Following treatment with insulin, a 5-fold increase in heme oxygenase-1 (HO-1) mRNA and a 4-fold increase in protein expression were observed in ACHN cells; insulin-induced HO-1 expression was also demonstrated in mouse primary tubular epithelial cells. The induction of HO-1 in ACHNs was blocked by actinomycin D and cycloheximide and was abolished by the PI3K inhibitor, LY294002, but not by the inactive analogue, LY303511. Over-expressing a dominant-negative form of Akt abrogated the HO-1 inducing effects of insulin, whereas cells transfected with a constitutively active Akt construct demonstrated an increase in HO-1 ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
According to experts, kidney cancer is one of the 10 most common forms of cancer in men and women alike. If you want to know some of the things that you may do to dodge this deadly disease, continue reading. Below we will discuss the risk factors for kidney cancer.. When risk factors are being talked about, things that are known to increase your likelihood of developing certain diseases are the ones involved. So in this case, risk factors for kidney cancer are those that can cause your odds of having cancer of the kidneys to increase.. Some risk factors for kidney cancer are non-preventable, which means that you have no control over them. Examples of these types of risk factors for kidney cancer are:. ...
Teaching Files with CT Medical Imaging and case studies on Anatomical Regions including Adrenal, Colon, Cardiac, Stomach, Pediatric, Spleen, Vascular, Kidney, Small Bowel, Liver, Chest | CTisus
All opinions expressed on the website are those of the respective authors and not of their employer. Information provided here is for medical education only. It is not intended as and does not substitute for medical advice. If you are a patient, please see your doctor for evaluation. The appearance of external hyperlinks to other websites does not constitute endorsement. We do not verify, endorse or take responsibility for the accuracy, currency, completeness or quality of the content contained in these sites. There is no real life patient data on this website. The Renal Fellow Network does not profit from any of the material on this website. No advertisements are accepted. The Renal Fellow Network is not funded by any agency or company. Any information collected by our website, such as email addresses, will never be passed on to any third party, unless required by law. The Renal Fellow Network is moderated occasionally and posteriorly. Moderators are volunteers. Internet users posting comments ...
Hybridization with cDNA arrays was used to obtain expression profiles of 214 protein-tyrosine kinase, protein-tyrosine phosphatase, dual specificity phosphatase, and other genes for kidney carcinomas (KC) and normal kidney tissues of 34 patients and for seven carcinoma cell lines. Computer analysis revealed three clusters of genes coexpressed in KC. The proliferating- cell gene cluster included MET, VIM, MYC, TOM, PCNA. The neoangiogenesis and blood-cell gene cluster included LCK, HCK, FGR, MAIM, CSFR1, VEGF, FLT1, and KDR. The cluster corresponding to normal, differentiated kidney cells included ERBB2 (HER2) for receptor protein-tyrosine kinase, several phosphatase genes (PTPRE, PTPRB, DUSP9), and EGF. The results suggested that MET, DUSP9, PCNA, TOM, and VIM may serve as diagnostic and prognostic markers in KC. Tubulin and topoisomerase II were assumed to be promising targets for cell proliferation inhibitors in KC. ...
Background: Genetic intratumoral heterogeneity (ITH) hinders biomarker development in metastatic clear cell renal cancer (mccRCC). Epigenetic relative to genetic ITH or the presence of consistent epigenetic changes following targeted therapy in mccRCC have not been evaluated. The aim of this study was to determine methylome/genetic ITH and to evaluate specific epigenetic and genetic changes associated with sunitinib therapy. ...
Part of the NBL Cell Line Collection. This cell line is neither produced nor fully characterized by ATCC. We do not guarantee that it will maintain a specific morphology, purity, or any other property upon passage.
Arm I: Patients receive induction therapy comprising interleukin-2 (IL-2) IV continuously over days 1-5, 15-19, 43-47, and 57-61 (weeks 1, 3, 7, and 9) and interferon alfa (IFN-α) subcutaneously (SC) three times weekly in weeks 1-3 and 7-9. Patients then undergo restaging. Patients achieving a complete response (CR), partial response (PR), or stable disease (SD) then receive maintenance therapy comprising IL-2 IV continuously over 5 days and IFN-α SC three times weekly in weeks 1, 5, 9, and 13 ...
Headline: Bitcoin & Blockchain Searches Exceed Trump! Blockchain Stocks Are Next!. Metastatic Renal Cell Carcinoma market report covers research informatics related to Metastatic Renal Cell Carcinoma clinical trials, such as a listing of industry and sponsored clinical trials as well as new drug therapies.. Designed to be a resource both for patients interested in participating in Metastatic Renal Cell Carcinoma clinical trials and for research professionals.. The report, Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016″ provides an overview of Metastatic Renal Cell Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Renal Cell Carcinoma. Report includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.. Browse ...
PURPOSE: Careful selection is critical to identify those with metastatic renal cell carcinoma who are most likely to benefit from cytoreductive nephrectomy. Surgery in patients who have metastatic renal cell carcinoma with tumor thrombus is complex and may not benefit some patients with poor overall survival. We evaluated whether preoperative variables or risk stratification systems could predict overall survival following cytoreductive nephrectomy.. MATERIALS AND METHODS: Prognostic factors for overall survival after surgery were evaluated in patients who had metastatic renal cell carcinoma with venous tumor thrombus at 5 institutions from 2000 to 2014. Prognostic variables, including metastatic renal cell carcinoma risk models, were evaluated for associations with overall survival. Multivariable analysis was used to determine independent associations of preoperative variables with overall survival.. RESULTS: A total of 427 patients with metastatic renal cell carcinoma were identified with ...
NOTOC__ For patient information click [[{{PAGENAME}} (patient information),here]] {{Renal cell carcinoma}} {{CMG}}; {{AE}} {{YD}}, {{SSK}}, {{SC}} {{SK}} RCC; Renal cell CA; Kidney cancer; Kidney carcinoma; Kidney CA; Grawitz tumor; Hypernephroma ==[[Renal cell carcinoma overview,Overview]]== ==[[Renal cell carcinoma historical perspective,Historical Perspective]]== ==[[Renal cell carcinoma classification,Classification]]== ==[[Renal cell carcinoma pathophysiology,Pathophysiology]]== ==[[Renal cell carcioma causes,Causes]]== ==[[Renal cell carcinoma differential diagnosis,Differentiating Renal cell carcinoma from other Diseases]]== ==[[Renal cell carcinoma epidemiology and demographics,Epidemiology and Demographics]]== ==[[Renal cell carcinoma risk factors,Risk Factors]]== ==[[Renal cell carcinoma screening,Screening]]== ==[[Renal cell carcinoma natural history, complications, and prognosis,Natural History, Complications and Prognosis]]== ==Diagnosis== [[Renal cell carcinoma ...
This paper presents the conclusions of a workshop entitled Impact of Molecular Genetics on the Classification of Renal Cell Tumours, which was held in Heidelberg in October 1996. The focus on renal cell tumours excludes any discussion of Wilms tumour and its variants, or of tumours metastatic to the kidneys. The proposed classification subdivides renal cell tumours into benign and malignant parenchymal neoplasms and, where possible, limits each subcategory to the most commonly documented genetic abnormalities. Benign tumours are subclassified into metanephric adenoma and adenofibroma, papillary renal cell adenoma, and renal oncocytoma. Malignant tumours are subclassified into common or conventional renal cell carcinoma; papillary renal cell carcinoma; chromophobe renal cell carcinoma; collecting duct carcinoma, with medullary carcinoma of the kidney; and renal cell carcinoma, unclassified. This classification is based on current genetic knowledge, correlates with recognizable histological ...
TY - JOUR. T1 - Vagina as a rare location of renal cell carcinoma metastasis. AU - Ladjevic, I. L.. AU - Stefanovic, A.. AU - Kadija, S.. AU - Terzic, M.. AU - Jeremic, K.. AU - Janjic, T.. PY - 2016/1/1. Y1 - 2016/1/1. N2 - Introduction: Metastatic renal cell carcinoma is often found in distant organs, including lung, bone, brain,and liver. Metastases to the vagina are extremely rare. Case Report: The authors present a case of renal cell carcinoma metastasis to the anterior vaginal wall four months after nephrectomy in a 56-year-old patient. The vaginal lesions were excised. After two years the patient had no signs of recurrence or the disease progression. Conclusion: Vaginal metastases should be considered in differential diagnosis of female renal cell carcinoma patients presenting with vaginal bleeding of mass.. AB - Introduction: Metastatic renal cell carcinoma is often found in distant organs, including lung, bone, brain,and liver. Metastases to the vagina are extremely rare. Case Report: ...
Title:Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). VOLUME: 8 ISSUE: 3. Author(s):Zofia F. Bielecka, Anna M. Czarnecka, Wojciech Solarek, Anna Kornakiewicz and Cezary Szczylik. Affiliation:Laboratory of Molecular Oncology, Department of Oncology, Military Institute of Medicine in Warsaw, Szaserów 128, 04-141 Warsaw, Poland.. Keywords:Acquired drug resistance, tyrosine kinase inhibitors, sunitinib, sorafenib, pazopanib, axitinib, tivozanib, epithelialmesenchymal transition, angiogenic switch, anti-angiogenic therapy, clear-cell renal cell carcinoma, non-genetic resistance mechanisms.. Abstract:Clear - cell renal cell carcinoma (ccRCC) is a histological subtype of renal cell carcinoma - the most prevalent adult kidney cancer. Causes of ccRCC are not completely understood and therefore number of available therapies is limited. As a consequence of tumor chemo- and radioresistance as well as restrictions in offered targeted therapies, ...
Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2 David M Gill1†, David D Stenehjem2†, Kinjal Parikh3, Jo
TY - JOUR. T1 - Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study. AU - Stroup, Sean P.. AU - Raheem, Omer A.. AU - Palazzi, Kerrin L.. AU - Liss, Michael A.. AU - Mehrazin, Reza. AU - Kopp, Ryan P.. AU - Patel, Nishant. AU - Cohen, Seth A.. AU - Park, Samuel K.. AU - Patterson, Anthony L.. AU - Kane, Christopher J.. AU - Millard, Frederick. AU - Derweesh, Ithaar H.. PY - 2013/4. Y1 - 2013/4. N2 - Objective: To compare outcomes of metastatic renal cell carcinoma (mRCC) patients who underwent primary cytoreductive nephrectomy (CRN), followed by adjuvant sunitinib therapy, vs those who underwent primary sunitinib therapy before planned CRN. Methods: This was a multi-institutional retrospective analysis of 35 mRCC patients from June 2005 to August 2009 (median follow-up, 28.5 months): 17 underwent primary CRN, followed by adjuvant sunitinib (group 1); 18 underwent primary sunitinib ...
TY - JOUR. T1 - Renal oncocytoma. T2 - A case report. AU - Akiyama, H.. AU - Shidahara, K.. AU - Nasu, Yasutomo. AU - Tsushima, T.. AU - Ohmori, H.. PY - 1995. Y1 - 1995. N2 - A case of renal oncocytoma is reported. A 79-year-old man was referred to our clinic because of a right renal mass pointed out by ultrasonography during a health check up. Computed tomography (CT), magnetic resonance imaging (MRI), angiography, and dynamic MRI suggested a right renal cell carcinoma. Rt. total nephrectomy was performed. A pathological diagnosis of renal oncocytoma was made. Renal oncocytoma is a rare benign renal tumor. We herein discuss 87 cases of renal oncocytoma which have been reported in Japan.. AB - A case of renal oncocytoma is reported. A 79-year-old man was referred to our clinic because of a right renal mass pointed out by ultrasonography during a health check up. Computed tomography (CT), magnetic resonance imaging (MRI), angiography, and dynamic MRI suggested a right renal cell carcinoma. Rt. ...
TY - JOUR. T1 - The impact of histology on survival for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. AU - Carrasco, Alonso. AU - Thompson, R. Houston. AU - Leibovich, Bradley C.. AU - Lohse, Christine M.. AU - Cheville, John C.. AU - Boorjian, Stephen A.. PY - 2014. Y1 - 2014. N2 - Objective: To evaluate the impact of histology on cancer-specific and overall survival for patients with metastatic renal cell carcinoma (mRCC) undergoing cytoreductive nephrectomy (CN). Materials and Methods: We retrospectively reviewed the data of 505 patients with mRCC who underwent CN at Mayo Clinic, Rochester, MN, USA, between 1970 and 2008. All specimen were re-reviewed by a single genitourinary pathologist. Survival was estimated using the Kaplan-Meier method and compared according to histology with the log-rank test. Cox proportional hazard regression models were used to evaluate the association of histology with outcome. Results: Forty (8%) patients with non-clear cell ...
TY - JOUR. T1 - Kidney size and cancer-specific survival for patients undergoing nephrectomy for pT1 clear cell renal cell carcinoma. AU - Jorns, Jacob J.. AU - Thiel, David D.. AU - Lohse, Christine. AU - Williams, Adrienne. AU - Arnold, Michelle. AU - Cheville, John. AU - Leibovich, Bradley. AU - Parker, Alexander S.. PY - 2012/7/1. Y1 - 2012/7/1. N2 - Objective: To examine the association between kidney size and renal cell carcinoma (RCC) death among patients with Stage pT1 clear cell RCC undergoing surgery. Methods: We used a case-cohort design and evaluated 191 patients from our Nephrectomy Registry who had undergone open radical nephrectomy for unilateral, sporadic, Stage pT1N0/NxM0, noncystic clear cell RCC from 1989 to 2004. Of these, 47 patients died of RCC (cases) and 144 patients were alive at the last follow-up visit or had died of other causes (cohort). Univariate and multivariate associations with RCC death were evaluated using weighted Cox regression analysis and summarized ...
Sumanta Pal, MD of City of Hope, Duarte, CA, discusses the introduction of new data of the new single-agent cabozantinib for advanced renal cell carcinoma. The agent is a dual MET and VEGFR2 inhibitor, and has been assessed in metastatic renal cell carcinoma and other diseases. Dr Pal highlights his involvement in the Phase I trials of cabozantinibs development in renal cell carcinoma, where impressive responses were observed. He proceeds to highlight that most recently, cabozantinib was used in a Phase III METEOR trial comparing it to the agent everolimus (NCT01865747). This study identified an improvement in response rate, overall survival (OS) and progression-free survival (PFS) for patients with advanced renal cell carcinoma. According to Dr Pal, these findings make the agent the optimal second-line choice in patients with metastatic renal cell carcinoma. He further adds that data from the CABOSUN study (NCT01835158), a clinical trial that compared sunitinib and cabozantinib in the front-line
TY - JOUR. T1 - Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma. AU - Buck, M. J.. AU - Raaijmakers, L. M.. AU - Ramakrishnan, S.. AU - Wang, D.. AU - Valiyaparambil, S.. AU - Liu, S.. AU - Nowak, N. J.. AU - Pili, Roberto. PY - 2014/10/9. Y1 - 2014/10/9. N2 - Recent studies have demonstrated that in clear cell renal cell carcinoma (ccRCC) several chromatin remodeling enzymes are genetically inactivated. Although, growing evidence in cancer models has demonstrated the importance of epigenetic changes, currently only changes in DNA methylation can be accurately determined from clinical samples. To address this limitation, we have applied formaldehyde-assisted isolation of regulatory elements (FAIREs) combined with next-generation sequencing (FAIRE-seq) to identify specific changes in chromatin accessibility in clinical samples of ccRCC. We modified the FAIRE procedure to allow us to examine chromatin accessibility for small samples of solid tumors. ...
Human Kidney Slide (Clear Cell Renal Cell Carcinoma) (5 slides/pk) Slide for IHC HTS-10405 Human Kidney Slide (Clear Cell Renal Cell Carcinoma) (5 slides/pk) Slide for IHC HTS-10405
Metachronous renal cell carcinoma after radical nephrectomy is extremely rare. Renal cell carcinoma commonly metastasizes to distant organs. However, metastasis to the urinary bladder is very uncommon. Herein, we report a case of metachronous renal cell carcinoma with metastasis to the urinary bladder, left acetabulum, left rib, lungs, thyroid, right renal vein and inferior vena cava. The patient had undergone a left-sided radical nephrectomy 28 years ago. The pathological diagnosis of a fragment of the bladder tumor was consistent with Fuhrman grade 2 clear cell renal cell carcinoma. Although metachronous renal cell carcinoma after radical nephrectomy is rare, active surveillance should be still considered. Renal cell carcinoma has shown to unusually metastasize to the urinary bladder, a rarely reported organ of metastasis. Treatment options, such as immunotherapy, are available to patients with such metastasis and long-term survivorship can be achieved.
TY - JOUR. T1 - Cloning of renal cell carcinoma relation gene. T2 - Construction of a cDNA subtractive library of human renal cell carcinoma and its significance. AU - Zhang, Qiang. AU - Mao, Ze Bin. AU - Zhang, Zhi Wen. AU - Xin, Dian Qi. AU - Guo, Ying Lu. PY - 2000/12/1. Y1 - 2000/12/1. N2 - To construct a cDNA subtractive library of human renal cell carcinoma (RCC) with technique called suppression subtractive hybridization. The library only contains the differently expressing cDNAs between RCC and normal kidney. Poly (A)+ RNA were isolated from cell lines of RCC and normal kidney respectively. Moreover, single-strand cDNAs and double-strand cDNAs were synthesized in turn. After enzyme restriction, cDNAs between 400600 bp were obtained. RCC cDNAs then were divided into two groups and ligated to the specific adaptor 1 and adaptor 2 respectively . After RCC cDNAs hybridized with normal kidney cDNA twice and underwent two times of nested PCR, then with arms of T/A plasmid vectors to set up the ...
Clear cell renal cell carcinoma (ccRCC) is the most common pathological subtype of renal cell carcinoma, and immune-related genes (IRGs) are key contributors to its development. In this study, the gene expression profiles and clinical data of ccRCC patients were downloaded from The Cancer Genome Atlas database and the cBioPortal database, respectively. IRGs were obtained from the ImmPort database. We analyzed the expression of IRGs in ccRCC, and discovered 681 that were differentially expressed between ccRCC and normal kidney tissues. Univariate Cox regression analysis was used to identify prognostic differentially expressed IRGs (PDEIRGs). Using Lasso regression and multivariate Cox regression analyses, we detected seven optimal PDEIRGs (PLAU, ISG15, IRF9, ARG2, RNASE2, SEMA3G and UCN) and used them to construct a risk model to predict the prognosis of ccRCC patients. This model accurately stratified patients with different survival outcomes and
List of Tables. Table 1: Clinical subtypes of Indication. Table 2: Risk Factors. Table 3: Prevalence cases (%) Region wise. Table 4: Sources used for forecasting the data. Table 5: Renal cell carcinoma Global Epidemiology, (2013-2023). Table 6: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), US (2013-2023). Table 7: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), US (2013-2023). Table 8: Prevalent Cases By Renal cell carcinoma Sub-population, US (2013-2023). Table 9: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), United Kingdom (2013-2023). Table 10: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), United Kingdom (2013-2023). Table 11: Prevalent Cases By Renal cell carcinoma Sub-population, United Kingdom (2013-2023). Table 12: Prevalent Cases of Renal cell carcinoma (Ages =XX Years), Germany (2013-2023). Table 13: Prevalent Cases of Renal cell carcinoma By Sex (Males & Females), Germany (2013-2023). Table 14: Prevalent Cases By Renal cell ...
Advanced Renal Cell Carcinoma (RCC) Market Research Report present a detailed analysis of the market listing Advanced Renal Cell Carcinoma (RCC) Epidemiology, Drug therapies and pipeline for study period from 2018-2030.
TY - JOUR. T1 - Intra-renal splenosis mimicking a solid renal mass. AU - Neufeld, Ethan A.. AU - Sekhon, Simran. AU - Gerscovich, Eugenio O. PY - 2017/8/1. Y1 - 2017/8/1. N2 - We present the case of a young woman found to have an exophytic solid renal mass who was referred to our institution for ablation of said mass versus partial nephrectomy. The patient had a history of splenectomy. Ultrasound demonstrated a homogeneous solid left renal mass, and the diagnosis of intra-renal splenosis was considered based on the patients history. The diagnosis was confirmed using Tc-99 m heat-damaged red blood cell scintigraphy, obviating the need for an invasive procedure. The diagnosis of intra-renal splenosis should be considered for a solid renal mass with an appropriate history of prior splenic trauma or splenectomy.. AB - We present the case of a young woman found to have an exophytic solid renal mass who was referred to our institution for ablation of said mass versus partial nephrectomy. The patient ...
Adding chemical shift techniques to MRI can help differentiate clear cell renal cell carcinoma from other types of renal cell cancer, a new study shows. That differentiation can help physicians better determine treatment for these patients.. The study, conducted at Massachusetts General Hospital in Boston, included 156 patients with proven renal cell cancer. Clear cell renal carcinoma contains microscopic areas of fat, which is not seen on conventional imaging, said Dr. Azadeh Elmi, lead author of the study. Chemical shift MRI enables us to quantify even small amounts of fat, she said. The study found that chemical shift MRI was about 83% accurate in differentiating clear cell renal cell carcinoma from other types of kidney cancer.. Clear cell type is the most common type of kidney cancer, and it has the greatest potential to metastasize, said Dr. Elmi. Chemical shift MRI is a protocol that can be readily performed in kidney MRI at no additional cost, she said. As we are moving toward less ...
BACKGROUND: The use of cytoreductive nephrectomy (CN) selectively for patients who show a favorable response to upfront systemic therapy may be an approach to select optimal candidates with metastatic renal cell carcinoma (mRCC) who are most likely to benefit.. OBJECTIVE: We sought to characterize outcomes of deferred CN (dCN) after upfront sunitinib, outcomes relative to sunitinib alone, and outcomes of CN followed by sunitinib.. DESIGN, SETTING, AND PARTICIPANTS: We used the prospectively maintained International mRCC Database Consortium (IMDC) database to identify patients with newly diagnosed mRCC (2006-2018).. INTERVENTION: Sunitinib alone, upfront CN followed by sunitinib, sunitinib followed by dCN.. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Outcomes were overall survival (OS) and time to sunitinib treatment failure (TTF). Kaplan-Meier and multivariable Cox regression analyses were performed; dCN was analyzed as a time-varying covariate to account for immortal time bias.. RESULTS AND ...
Full Text - In this study, we performed bioinformatics and statistical analyses to investigate the prognostic significance of metabolic genes in clear cell renal cell carcinoma (ccRCC) using the transcriptome data of 539 ccRCC and 72 normal renal tissues from TCGA database. We identified 79 upregulated and 45 downregulated (n=124) metabolic genes in ccRCC tissues. Eleven prognostic metabolic genes (NOS1, ALAD, ALDH3B2, ACADM, ITPKA, IMPDH1, SCD5, FADS2, ACHE, CA4, and HK3) were identified by further analysis. We then constructed an 11-metabolic gene signature-based prognostic risk score model and classified ccRCC patients into high- and low-risk groups. Overall survival (OS) among the high-risk ccRCC patients was significantly shorter than among the low-risk ccRCC patients. Receiver operating characteristic (ROC) curve analysis of the prognostic risk score model showed that the areas under the ROC curve for the 1-, 3-, and 5-year OS were 0.810, 0.738, and 0.771, respectively. Thus, our prognostic
Clinical trial for Renal Cell Carcinoma | urinary tract cancer | Bladder Urothelial Carcinoma | Transitional Cell Carcinoma of the Bladder | Metastatic Kidney Carcinoma | clear cell renal cell carcinoma | Malignant Adenoma | Stage IV Renal Cell Cancer AJCC v8 | Adenocarcinoma | transitional cell carcinoma of bladder | Malignant neoplasm of kidney | Renal Cancer | Urologic Cancer | Renal Cell Cancer | Malignant Neoplasms of Urinary Tract | Kidney Cancer | urinary tract neoplasm , Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373:1119-32 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69:7-34 3. Campbell S, Uzzo RG, Allaf ME, Bass EB, Cadeddu JA, Chang A. et al. Renal Mass and Localized Renal Cancer: AUA Guideline. The Journal of urology. 2017;198:520-9 4. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M. et al. EAU guidelines on renal cell carcinoma: 2014 update. European urology. 2015;67:913-24 5. Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387:894-906 6. Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A. et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. European urology. 2011;59:543-52 7. Crispen PL, Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC. et al. Lymph node dissection at the time of radical ...
Through combined deletion of Vhl, Trp53 and Rb1 in renal epithelial cells, the authors develop a new mouse model of renal cell carcinoma that recapitulates the cellular and molecular features of a large proportion of human tumors. This model uncovers a role for primary-cilium-related genes in the development of the disease and provides a reliable platform for preclinical therapeutic studies. Clear cell renal cell carcinomas (ccRCCs) frequently exhibit inactivation of the von Hippel-Lindau tumor-suppressor gene, VHL, and often harbor multiple copy-number alterations in genes that regulate cell cycle progression. We show here that modeling these genetic alterations by combined deletion of Vhl, Trp53 and Rb1 specifically in renal epithelial cells in mice caused ccRCC. These tumors arose from proximal tubule epithelial cells and shared molecular markers and mRNA expression profiles with human ccRCC. Exome sequencing revealed that mouse and human ccRCCs exhibit recurrent mutations in genes associated with
ABSTRACT. Cell cycle regulation in human renal cell carcinoma. Ylva Hedberg, Departments of Medical Biosciences, Pathology, and Surgical and. Perioperative Sciences, Urology Andrology, Umeå University, Sweden. Deregulated growth control is a hallmark of neoplasia potentially caused by aberrant expression of cell cycle regulatory proteins. The importance of such aberrations in human renal cell carcinoma (RCC) has not been fully clarified. Therefore, the protein expressions of several G1/S regulatory proteins in human RCC were evaluated and their relation to clinico-pathological data was examined.. Western blotting and immunohistochemistry were used to detect the proteinexpression of cyclin D1, D3, and E in 80 RCCs. Most tumors expressed higher levels of cyclin D1 (75%) and cyclin E (65%) compared to corresponding normal kidney cortex. In contrast, only 16 % of the tumors had high levels of cyclin D3. In conventional RCCs, low levels of cyclin D1 were associated with large tumor size, aneuploidy ...
Objective: Our study aims to investigate the mechanism of the miR-129-5p/SPN axis in clear cell renal cell carcinoma (ccRCC), providing a novel direction for the targeted therapy of ccRCC. Methods: Bioinformatics methods were implemented to find the dif...
BACKGROUND: The prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical significance of COX-2 in clear cell RCC (CCRCC) and to assess the treatment effect of COX-2 inhibition on CCRCC cell lines. METHODS: Using tumor samples obtained from 137 patients who had undergone nephrectomy at Seoul National University Hospital, we evaluated COX-2 expression on immunohistochemistry. Moreover, we performed the cell proliferation assay using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) and cell invasion assay. Thus, we evaluated the effect of meloxicam, an inhibitor of COX-2, in two human CCRCC cell lines. RESULTS: Cancer-specific survival (p=0.038) and progression-free survival (p=0.031) were shorter in the COX-2 high expression group. A multivariate logistic regression model showed that COX-2 expression was an independent risk factor for pTNM stage and Fuhrman nuclear grade. The MTT ...
TY - JOUR. T1 - Does Obesity Impact the Costs of Partial and Radical Nephrectomy?. AU - Bensalah, Karim. AU - Raman, Jay D.. AU - Bagrodia, Aditya. AU - Marvin, Andrea. AU - Lotan, Yair. PY - 2008/5/1. Y1 - 2008/5/1. N2 - Purpose: We analyzed the impact of obesity on the costs of partial and radical nephrectomy. Materials and Methods: The charts of 237 patients who underwent open radical nephrectomy (48), laparoscopic radical nephrectomy (67), open partial nephrectomy (61) or laparoscopic partial nephrectomy (61) were retrospectively reviewed. Clinical data were collected, including age, American Society of Anesthesiologists score, body mass index, tumor size, complications and length of stay. Cost data comprised total direct costs and subcosts, including anesthesia, laboratory, operating room service, radiology, room and board, pharmacy and surgical supplies. Obese and nonobese patients were compared in each group using the Mann-Whitney U and chi-square tests for continuous and categorical ...
TY - JOUR. T1 - A cohort study of reproductive and hormonal factors and renal cell cancer risk in women. AU - Kabat, G. C.. AU - Navarro Silvera, S. A.. AU - Miller, A. B.. AU - Rohan, T. E.. PY - 2007/3/12. Y1 - 2007/3/12. N2 - We examined the association of reproductive and hormonal factors with renal cell cancer risk in a cohort study of 89 835 Canadian women. Compared with nulliparous women, parous women were at increased risk (hazard ratio (HR) 1.78, 95% confidence interval (CI) 1.02-3.09), and there was a significant gradient of risk with increasing levels of parity: relative to nulliparous women, women who had ≥5 pregnancies lasting 4 months or more had a 2.4-fold risk (HR=2.41, 95% CI=1.27-4.59, P for trend 0.01). Ever use of oral contraceptives was associated with a modest reduction in risk. No associations were observed for age at first live birth or use of hormone replacement therapy. The present study provides evidence that high parity may be associated with increased risk of renal ...
Protein-coding mutations in clear cell renal cell carcinoma (ccRCC) have been extensively characterized, frequently involving inactivation of the von Hippel-Lindau (VHL) tumor suppressor. Roles for noncoding cis-regulatory aberrations in ccRCC tumorigenesis, however, remain unclear. Analyzing 10 primary tumor/normal pairs and 9 cell lines across 79 chromatin profiles, we observed pervasive enhancer malfunction in ccRCC, with cognate enhancer-target genes associated with tissue-specific aspects of malignancy. Superenhancer profiling identified ZNF395 as a ccRCC-specific and VHL-regulated master regulator whose depletion causes near-complete tumor elimination in vitro and in vivo. VHL loss predominantly drives enhancer/superenhancer deregulation more so than promoters, with acquisition of active enhancer marks (H3K27ac, H3K4me1) near ccRCC hallmark genes. Mechanistically, VHL loss stabilizes HIF2α-HIF1β heterodimer binding at enhancers, subsequently recruiting histone acetyltransferase p300 ...
Preoperative renal tumor subtype differentiation is definitely important for radiology and urology in clinical practice. vs 40.3180.4833 vs 50.0130.1654 vs 5 0.0010.411 Open in a separate window Note: 1: clear cell renal cell carcinoma; 2: papillary renal cell carcinoma; 3: chromophobic renal cell carcinoma; 4: uroepithelial carcinoma; 5: fat-poor angiomyolipoma. Open in a separate window Figure 3 Box-and-whisker plot of em K /em trans value. Boxes?=?interquartile range, whiskers?=?range of all values, horizontal line within box?=?median em K /em trans, ccRCC?=?clear cell RCC, pRCC?=?papillary RCC, cRCC?=?chromophobic RCC, UEC?=?uroepithelial carcinoma, fpAML?=?fat poor angiomyolipoma. Open in a separate window Figure 4 Box-and-whisker plot of em V /em e value. Boxes?=?interquartile range, whiskers?=?range of all values, horizontal line within box?=?median em V /em e, ccRCC?=?clear cell RCC, pRCC?=?papillary RCC, cRCC?=?chromophobic RCC, UEC?=?uroepithelial carcinoma, fpAML?=?fat poor ...
The median age was 57 years (range 30-80). Most patients underwent a nephrectomy (n = 41; 70.7%), were male (n = 42; 72.4%) and had clear-cell (CC) RCC (n = 51; 87.9%). Patients were treated with first-line sunitinib (n = 45; 77.6%) or pazopanib (n = 13; 22.4%). The median time from the initial RCC diagnosis to the diagnosis of BMs was 9 months. The median time from the first occurrence of metastasis to the development of BMs was 7 months. The median overall survival (OS) of mRCC patients with BMs was 13 months. Time from the initial diagnosis of systemic metastasis to the development of BMs (,12 months; p = 0.001), histological subtype (non-CC; p,0.05) and number of BMs (≥2; p,0.05) were significantly associated with OS in multivariate analysis. There were no cases of toxic death. One mRCC patient with BMs (1.7%) experienced treatment-related cerebral necrosis. All other toxicities included those commonly observed with VEGF-TKI therapy.. ...
Bristol-Myers Squibb has announced the early closure of its phase 3 CheckMate-025 trial evaluating nivolumab (Opdivo) compared with everolimus for the treatment of previously-treated patients with advanced or metastatic renal cell carcinoma.. The study was stopped early because an independent Data Monitoring Committee assessment found that nivolumab is superior to everolimus in this patient population.. The results of CheckMate-025 mark the first time an Immuno-Oncology agent has demonstrated a survival advantage in advanced renal cell carcinoma, a patient group that currently has limited treatment options, said Michael Giordano, senior vice president, Head of Development, Oncology, Bristol-Myers Squibb. Through our Opdivo clinical development program, we aim to redefine treatment expectations for patients with advanced RCC by providing improved survival.. For the open-label trial, 821 previously-treated patients with advanced or metastatic clear-cell renal cell carcinoma were randomly ...
Preliminary data from an interim analysis of an ongoing phase III clinical trial of investigational temsirolimus (CCI-779) for the treatment of advanced renal cell carcinoma showed that single-agent therapy with temsirolimus significantly increased overall survival as a first-line treatment of patients with advanced disease and poor-risk features compared to interferon-alpha, a treatment for advanced renal cell carcinoma. In the trial, patients who were treated with temsirolimus alone experienced a 3.6-month, or 49%, increase in median overall survival time compared with patients treated with interferon-alpha alone (10.9 vs 7.3 months, P = .0069). 1
The bevacizumab experience in advanced renal cell carcinoma Lauren C Harshman, Sandy SrinivasDivision of Oncology, Stanford University School of Medicine, Stanford, California, USAAbstract: Bevacizumab in combination with interferon alfa is now approved for treatment-naïve advanced renal cell carcinoma (RCC) in both the US and Europe. Its objective response rates of 30% and progression-free survival rates of 9–10 months are ­comparable to the other approved first-line multityrosine kinase inhibitors, sunitinib and pazopanib. Its advantages include a different toxicity profile and assurance of ­administration compliance given its intravenous formulation. Enthusiasm for its use is blunted by the increased costs, the potential infusion-related reactions, the associated interferon-related toxicities, and the inconvenience of its nonoral formulation. Further study is warranted to assess its efficacy both as a single agent and in combination with the targeted agents and other
Riboflavin (vitamin B2) is a precursor for coenzymes involved in energy production, biosynthesis, detoxification, and electron scavenging. Previously, we demonstrated that irradiated riboflavin (IR)...
Background:It has been suggested that the apparent protective effect of alcohol intake on renal cell carcinoma may be due to the diluting effect of carcinogens by a high total fluid intake. We assessed the association between intakes of total fluids and of specific beverages on the risk of renal cell carcinoma in a large prospective cohort of UK women.Methods:Information on beverage consumption was obtained from a questionnaire sent 3 years after recruitment into the Million Women Study. Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) for renal cell carcinoma associated with beverage consumption adjusted for age, region of residence, socioeconomic status, smoking, and body mass index.Results:After an average of 5.2 years of follow-up, 588 cases of renal cell carcinoma were identified among 779 369 women. While alcohol intake was associated with a reduced risk of renal cell carcinoma (RR for 2 vs 1 drink per day: 0.76; 95% CI: 0.61-0.96; P for
This research study is comparing different drug combinations as a possible treatment for metastatic renal cell carcinoma (mRCC) and bone metastases. The names
TY - JOUR. T1 - Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR). T2 - final results from a randomised, open-label, phase 3 trial. AU - Choueiri, Toni K.. AU - Escudier, Bernard. AU - Powles, Thomas. AU - Tannir, Nizar M.. AU - Mainwaring, Paul N.. AU - Rini, Brian I.. AU - Hammers, Hans J.. AU - Donskov, Frede. AU - Roth, Bruce J.. AU - Peltola, Katriina. AU - Lee, Jae Lyun. AU - Heng, Daniel Y C. AU - Schmidinger, Manuela. AU - Agarwal, Neeraj. AU - Sternberg, Cora N.. AU - McDermott, David F.. AU - Aftab, Dana T.. AU - Hessel, Colin. AU - Scheffold, Christian. AU - Schwab, Gisela. AU - Hutson, Thomas E.. AU - Pal, Sumanta. AU - Motzer, Robert J.. AU - METEOR investigators. PY - 2016/7/1. Y1 - 2016/7/1. N2 - Background Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR, and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with advanced renal cell carcinoma ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
The term RCC encompasses a highly heterogeneous group of malignancies, from both a morphological and a molecular point of view, but emerging evidence indicates that common molecular paths to renal carcinogenesis do exist and may justify, to some extent, shared approaches to the clinical treatment of different RCC subtypes (2). Although most of RCC cases occur in a sporadic form, both clear cell and non-clear cell RCC can occur in the context of inherited cancer syndromes, whose molecular genetics has shed light on potentially common molecular pathogenetic themes (3-4). This is probably best exemplified by von Hippel-Lindau disease (VHL) and tuberous sclerosis (TS), two autosomal dominant inherited syndromes with variable penetrance that carry a high lifetime risk of developing clear cell RCC (5-6). The VHL gene, which targets hypoxia inducible factor (HIF)-1α for degradation by the proteasome, is mutated or silenced in up to 75% of sporadic clear cell RCC, suggesting that genetic abnormalities ...